VRCA
NASDAQVerrica Pharmaceuticals Inc.
Price$6.44-0.06 (-1.00%)
03:45 PM07:45 PM
News · 26 weeks370%
2025-10-262026-04-19
Mix1490d
- Offering4(29%)
- SEC Filings4(29%)
- Other3(21%)
- Insider2(14%)
- Earnings1(7%)
Latest news
25 items- SECSEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form DEF 14A filed by Verrica Pharmaceuticals Inc.DEF 14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingWEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica's novel oncolytic peptide for the treatment of basal cell carcinoma. The data will be presented at the upcoming 2026 Society for Investigative Dermatology (SID) Annual Meeting, which will take place from May 13-16, 2026, in Chicago, Illinois. Presentation Details: Title: "VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Targ
- PRVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceWEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026Event details:Date: Wednesday, April 15, 2026Time: 3:00pm ETLocation: Virtual Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the I
- SECSEC Form 10-K filed by Verrica Pharmaceuticals Inc.10-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate
- PRVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di
- PRVerrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceWEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday, March 2, 2026Time: 10:30am ETLocation: Boston, Massachusetts Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/P
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.SCHEDULE 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
- PRVerrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial OfficerWEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. "It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. "Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and co
- PRVerrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii PharmaceuticalWEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. ("Torii"), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum ("molluscum"). "We would like to congratulate our partner, Torii, on the launch of YCANTH in Japan for the treatment of molluscum. Torii's achievement also represents an exciting milestone for Verrica, as we continue to execute on our long-term strategy of developing a
- INSIDERAmendment: SEC Form 3 filed by new insider Bkb Growth Investments, Llc3/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERNew insider Bkb Growth Investments, Llc claimed ownership of 3,348,372 shares (SEC Form 3)3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- PRVerrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. "The
- INSIDERInterim CFO Kirby John J. was granted 10,000 shares, increasing direct ownership by 112% to 18,962 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Verrica Pharmaceuticals Inc.SCHEDULE 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
- INSIDERNew insider Caligan Partners Lp claimed ownership of 923,910 shares (SEC Form 3)3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 3 filed by new insider Frantzreb Charles3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- SECSEC Form 8-K filed by Verrica Pharmaceuticals Inc.8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form EFFECT filed by Verrica Pharmaceuticals Inc.EFFECT - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form 424B3 filed by Verrica Pharmaceuticals Inc.424B3 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form S-3 filed by Verrica Pharmaceuticals Inc.S-3 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form D filed by Verrica Pharmaceuticals Inc.D - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Verrica Pharmaceuticals Inc.SCHEDULE 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)